Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Research Report 2024

Report ID: 1969787 | Published Date: Jan 2025 | No. of Page: 95 | Base Year: 2024 | Rating: 5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 SX-PCK9
        1.2.3 O-304
        1.2.4 K-312
        1.2.5 BLSM-201
        1.2.6 DCRPCSK-9
        1.2.7 Others
    1.3 Market by Application
        1.3.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Cardiovascular Disease
        1.3.3 Homozugous Familial Hyperchalesterolemia
        1.3.4 Liver Disease
        1.3.5 Metabolic Syndrome
        1.3.6 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Perspective (2017-2028)
    2.2 Proprotein Convertase Subtilisin & Kexin Type 9 Growth Trends by Region
        2.2.1 Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Proprotein Convertase Subtilisin & Kexin Type 9 Historic Market Size by Region (2017-2022)
        2.2.3 Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Region (2023-2028)
    2.3 Proprotein Convertase Subtilisin & Kexin Type 9 Market Dynamics
        2.3.1 Proprotein Convertase Subtilisin & Kexin Type 9 Industry Trends
        2.3.2 Proprotein Convertase Subtilisin & Kexin Type 9 Market Drivers
        2.3.3 Proprotein Convertase Subtilisin & Kexin Type 9 Market Challenges
        2.3.4 Proprotein Convertase Subtilisin & Kexin Type 9 Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Proprotein Convertase Subtilisin & Kexin Type 9 Players by Revenue
        3.1.1 Global Top Proprotein Convertase Subtilisin & Kexin Type 9 Players by Revenue (2017-2022)
        3.1.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Players (2017-2022)
    3.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Proprotein Convertase Subtilisin & Kexin Type 9 Revenue
    3.4 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Concentration Ratio
        3.4.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Proprotein Convertase Subtilisin & Kexin Type 9 Revenue in 2021
    3.5 Proprotein Convertase Subtilisin & Kexin Type 9 Key Players Head office and Area Served
    3.6 Key Players Proprotein Convertase Subtilisin & Kexin Type 9 Product Solution and Service
    3.7 Date of Enter into Proprotein Convertase Subtilisin & Kexin Type 9 Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Proprotein Convertase Subtilisin & Kexin Type 9 Breakdown Data by Type
    4.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Historic Market Size by Type (2017-2022)
    4.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Type (2023-2028)
5 Proprotein Convertase Subtilisin & Kexin Type 9 Breakdown Data by Application
    5.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Historic Market Size by Application (2017-2022)
    5.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2017-2028)
    6.2 North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2017-2022)
    6.3 North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2017-2028)
    7.2 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2017-2022)
    7.3 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2017-2028)
    8.2 Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2017-2022)
    8.3 Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2017-2028)
    9.2 Latin America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2017-2022)
    9.3 Latin America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2017-2028)
    10.2 Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2017-2022)
    10.3 Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 AFFiRiS AG
        11.1.1 AFFiRiS AG Company Detail
        11.1.2 AFFiRiS AG Business Overview
        11.1.3 AFFiRiS AG Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.1.4 AFFiRiS AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.1.5 AFFiRiS AG Recent Development
    11.2 Betagenon AB
        11.2.1 Betagenon AB Company Detail
        11.2.2 Betagenon AB Business Overview
        11.2.3 Betagenon AB Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.2.4 Betagenon AB Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.2.5 Betagenon AB Recent Development
    11.3 Bioleaders Corp
        11.3.1 Bioleaders Corp Company Detail
        11.3.2 Bioleaders Corp Business Overview
        11.3.3 Bioleaders Corp Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.3.4 Bioleaders Corp Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.3.5 Bioleaders Corp Recent Development
    11.4 BioLingus AG
        11.4.1 BioLingus AG Company Detail
        11.4.2 BioLingus AG Business Overview
        11.4.3 BioLingus AG Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.4.4 BioLingus AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.4.5 BioLingus AG Recent Development
    11.5 Catabasis Pharmaceuticals Inc
        11.5.1 Catabasis Pharmaceuticals Inc Company Detail
        11.5.2 Catabasis Pharmaceuticals Inc Business Overview
        11.5.3 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.5.4 Catabasis Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.5.5 Catabasis Pharmaceuticals Inc Recent Development
    11.6 Dicerna Pharmaceuticals Inc
        11.6.1 Dicerna Pharmaceuticals Inc Company Detail
        11.6.2 Dicerna Pharmaceuticals Inc Business Overview
        11.6.3 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.6.4 Dicerna Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.6.5 Dicerna Pharmaceuticals Inc Recent Development
    11.7 Eli Lilly and Co
        11.7.1 Eli Lilly and Co Company Detail
        11.7.2 Eli Lilly and Co Business Overview
        11.7.3 Eli Lilly and Co Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.7.4 Eli Lilly and Co Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.7.5 Eli Lilly and Co Recent Development
    11.8 Ensemble Therapeutics Corp
        11.8.1 Ensemble Therapeutics Corp Company Detail
        11.8.2 Ensemble Therapeutics Corp Business Overview
        11.8.3 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.8.4 Ensemble Therapeutics Corp Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.8.5 Ensemble Therapeutics Corp Recent Development
    11.9 Kowa Co Ltd
        11.9.1 Kowa Co Ltd Company Detail
        11.9.2 Kowa Co Ltd Business Overview
        11.9.3 Kowa Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.9.4 Kowa Co Ltd Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.9.5 Kowa Co Ltd Recent Development
    11.10 Novartis AG
        11.10.1 Novartis AG Company Detail
        11.10.2 Novartis AG Business Overview
        11.10.3 Novartis AG Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.10.4 Novartis AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.10.5 Novartis AG Recent Development
    11.11 Pfizer Inc
        11.11.1 Pfizer Inc Company Detail
        11.11.2 Pfizer Inc Business Overview
        11.11.3 Pfizer Inc Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.11.4 Pfizer Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.11.5 Pfizer Inc Recent Development
    11.12 Regeneron Pharmaceuticals Inc
        11.12.1 Regeneron Pharmaceuticals Inc Company Detail
        11.12.2 Regeneron Pharmaceuticals Inc Business Overview
        11.12.3 Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.12.4 Regeneron Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.12.5 Regeneron Pharmaceuticals Inc Recent Development
    11.13 Serometrix LLC
        11.13.1 Serometrix LLC Company Detail
        11.13.2 Serometrix LLC Business Overview
        11.13.3 Serometrix LLC Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.13.4 Serometrix LLC Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.13.5 Serometrix LLC Recent Development
    11.14 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
        11.14.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Detail
        11.14.2 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Business Overview
        11.14.3 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.14.4 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.14.5 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Development
    11.15 The Medicines Company
        11.15.1 The Medicines Company Company Detail
        11.15.2 The Medicines Company Business Overview
        11.15.3 The Medicines Company Proprotein Convertase Subtilisin & Kexin Type 9 Introduction
        11.15.4 The Medicines Company Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
        11.15.5 The Medicines Company Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of SX-PCK9
    Table 3. Key Players of O-304
    Table 4. Key Players of K-312
    Table 5. Key Players of BLSM-201
    Table 6. Key Players of DCRPCSK-9
    Table 7. Key Players of Others
    Table 8. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 10. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region (2017-2022) & (US$ Million)
    Table 11. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Region (2017-2022)
    Table 12. Global Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 13. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Region (2023-2028)
    Table 14. Proprotein Convertase Subtilisin & Kexin Type 9 Market Trends
    Table 15. Proprotein Convertase Subtilisin & Kexin Type 9 Market Drivers
    Table 16. Proprotein Convertase Subtilisin & Kexin Type 9 Market Challenges
    Table 17. Proprotein Convertase Subtilisin & Kexin Type 9 Market Restraints
    Table 18. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Players (2017-2022) & (US$ Million)
    Table 19. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Players (2017-2022)
    Table 20. Global Top Proprotein Convertase Subtilisin & Kexin Type 9 Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 as of 2021)
    Table 21. Ranking of Global Top Proprotein Convertase Subtilisin & Kexin Type 9 Companies by Revenue (US$ Million) in 2021
    Table 22. Global 5 Largest Players Market Share by Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (CR5 and HHI) & (2017-2022)
    Table 23. Key Players Headquarters and Area Served
    Table 24. Key Players Proprotein Convertase Subtilisin & Kexin Type 9 Product Solution and Service
    Table 25. Date of Enter into Proprotein Convertase Subtilisin & Kexin Type 9 Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Type (2017-2022) & (US$ Million)
    Table 28. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Type (2017-2022)
    Table 29. Global Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 30. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Type (2023-2028)
    Table 31. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Application (2017-2022) & (US$ Million)
    Table 32. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Application (2017-2022)
    Table 33. Global Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 34. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Application (2023-2028)
    Table 35. North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2017-2022) & (US$ Million)
    Table 36. North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2023-2028) & (US$ Million)
    Table 37. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2017-2022) & (US$ Million)
    Table 38. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2023-2028) & (US$ Million)
    Table 39. Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region (2017-2022) & (US$ Million)
    Table 40. Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region (2023-2028) & (US$ Million)
    Table 41. Latin America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2017-2022) & (US$ Million)
    Table 42. Latin America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2023-2028) & (US$ Million)
    Table 43. Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2017-2022) & (US$ Million)
    Table 44. Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2023-2028) & (US$ Million)
    Table 45. AFFiRiS AG Company Detail
    Table 46. AFFiRiS AG Business Overview
    Table 47. AFFiRiS AG Proprotein Convertase Subtilisin & Kexin Type 9 Product
    Table 48. AFFiRiS AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 49. AFFiRiS AG Recent Development
    Table 50. Betagenon AB Company Detail
    Table 51. Betagenon AB Business Overview
    Table 52. Betagenon AB Proprotein Convertase Subtilisin & Kexin Type 9 Product
    Table 53. Betagenon AB Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 54. Betagenon AB Recent Development
    Table 55. Bioleaders Corp Company Detail
    Table 56. Bioleaders Corp Business Overview
    Table 57. Bioleaders Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product
    Table 58. Bioleaders Corp Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 59. Bioleaders Corp Recent Development
    Table 60. BioLingus AG Company Detail
    Table 61. BioLingus AG Business Overview
    Table 62. BioLingus AG Proprotein Convertase Subtilisin & Kexin Type 9 Product
    Table 63. BioLingus AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 64. BioLingus AG Recent Development
    Table 65. Catabasis Pharmaceuticals Inc Company Detail
    Table 66. Catabasis Pharmaceuticals Inc Business Overview
    Table 67. Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product
    Table 68. Catabasis Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 69. Catabasis Pharmaceuticals Inc Recent Development
    Table 70. Dicerna Pharmaceuticals Inc Company Detail
    Table 71. Dicerna Pharmaceuticals Inc Business Overview
    Table 72. Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product
    Table 73. Dicerna Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 74. Dicerna Pharmaceuticals Inc Recent Development
    Table 75. Eli Lilly and Co Company Detail
    Table 76. Eli Lilly and Co Business Overview
    Table 77. Eli Lilly and Co Proprotein Convertase Subtilisin & Kexin Type 9 Product
    Table 78. Eli Lilly and Co Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 79. Eli Lilly and Co Recent Development
    Table 80. Ensemble Therapeutics Corp Company Detail
    Table 81. Ensemble Therapeutics Corp Business Overview
    Table 82. Ensemble Therapeutics Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product
    Table 83. Ensemble Therapeutics Corp Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 84. Ensemble Therapeutics Corp Recent Development
    Table 85. Kowa Co Ltd Company Detail
    Table 86. Kowa Co Ltd Business Overview
    Table 87. Kowa Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product
    Table 88. Kowa Co Ltd Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 89. Kowa Co Ltd Recent Development
    Table 90. Novartis AG Company Detail
    Table 91. Novartis AG Business Overview
    Table 92. Novartis AG Proprotein Convertase Subtilisin & Kexin Type 9 Product
    Table 93. Novartis AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 94. Novartis AG Recent Development
    Table 95. Pfizer Inc Company Detail
    Table 96. Pfizer Inc Business Overview
    Table 97. Pfizer Inc Proprotein Convertase Subtilisin & Kexin Type 9Product
    Table 98. Pfizer Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 99. Pfizer Inc Recent Development
    Table 100. Regeneron Pharmaceuticals Inc Company Detail
    Table 101. Regeneron Pharmaceuticals Inc Business Overview
    Table 102. Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9Product
    Table 103. Regeneron Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 104. Regeneron Pharmaceuticals Inc Recent Development
    Table 105. Serometrix LLC Company Detail
    Table 106. Serometrix LLC Business Overview
    Table 107. Serometrix LLC Proprotein Convertase Subtilisin & Kexin Type 9Product
    Table 108. Serometrix LLC Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 109. Serometrix LLC Recent Development
    Table 110. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Detail
    Table 111. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Business Overview
    Table 112. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9Product
    Table 113. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 114. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Development
    Table 115. The Medicines Company Company Detail
    Table 116. The Medicines Company Business Overview
    Table 117. The Medicines Company Proprotein Convertase Subtilisin & Kexin Type 9Product
    Table 118. The Medicines Company Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022) & (US$ Million)
    Table 119. The Medicines Company Recent Development
    Table 120. Research Programs/Design for This Report
    Table 121. Key Data Information from Secondary Sources
    Table 122. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Type: 2021 VS 2028
    Figure 2. SX-PCK9 Features
    Figure 3. O-304 Features
    Figure 4. K-312 Features
    Figure 5. BLSM-201 Features
    Figure 6. DCRPCSK-9 Features
    Figure 7. Others Features
    Figure 8. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Application in 2021 & 2028
    Figure 9. Cardiovascular Disease Case Studies
    Figure 10. Homozugous Familial Hyperchalesterolemia Case Studies
    Figure 11. Liver Disease Case Studies
    Figure 12. Metabolic Syndrome Case Studies
    Figure 13. Others Case Studies
    Figure 14. Proprotein Convertase Subtilisin & Kexin Type 9 Report Years Considered
    Figure 15. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 16. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 17. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Region: 2021 VS 2028
    Figure 18. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Players in 2021
    Figure 19. Global Top Proprotein Convertase Subtilisin & Kexin Type 9 Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 as of 2021)
    Figure 20. The Top 10 and 5 Players Market Share by Proprotein Convertase Subtilisin & Kexin Type 9 Revenue in 2021
    Figure 21. North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Country (2017-2028)
    Figure 23. United States Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Canada Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Country (2017-2028)
    Figure 27. Germany Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. France Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. U.K. Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Italy Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Russia Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Nordic Countries Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Region (2017-2028)
    Figure 35. China Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Japan Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. South Korea Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Southeast Asia Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. India Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Australia Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Latin America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Latin America Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Country (2017-2028)
    Figure 43. Mexico Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Brazil Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Country (2017-2028)
    Figure 47. Turkey Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 48. Saudi Arabia Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 49. AFFiRiS AG Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 50. Betagenon AB Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 51. Bioleaders Corp Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 52. BioLingus AG Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 53. Catabasis Pharmaceuticals Inc Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 54. Dicerna Pharmaceuticals Inc Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 55. Eli Lilly and Co Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 56. Ensemble Therapeutics Corp Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 57. Kowa Co Ltd Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 58. Novartis AG Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 59. Pfizer Inc Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 60. Regeneron Pharmaceuticals Inc Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 61. Serometrix LLC Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 62. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 63. The Medicines Company Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2017-2022)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AFFiRiS AG
Betagenon AB
Bioleaders Corp
BioLingus AG
Catabasis Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Eli Lilly and Co
Ensemble Therapeutics Corp
Kowa Co Ltd
Novartis AG
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The Medicines Company
Frequently Asked Questions
Proprotein Convertase Subtilisin & Kexin Type 9 report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Proprotein Convertase Subtilisin & Kexin Type 9 report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Proprotein Convertase Subtilisin & Kexin Type 9 report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports